VistaGen Therapeutics (NASDAQ: VTGN) Featured Research Report

8 A EGIS C APITAL C ORP. Fig. 5. PH94B Phase 3 study design Source: VistaGen VistaGen Therapeutics, Inc. October 8, 2020